Active, not recruitingPhase 3NCT04582136

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Chinese SLE Treatment And Research Group
Principal Investigator: Xiaofeng Zeng, MD
Chinese SLE Treatment and Registration Group
Intervention: Sirolimus(drug)
Enrollment: 146 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2021 – 2026

Study locations (6)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Shenzhen People's Hospital, Shenzhen, Guangdong, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

Collaborators

Beijing Municipal Science & Technology Commission · North China Pharmaceutical Group Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04582136 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials